Loading...

ADVM ADVERUM BIOTECHNOLOGIES INC Dividend Policy Changes 8-K Filing

DVRM

DVM

ADVERUM BIOTECHNOLOGIES INC

(ADVM)

2025 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

Financial Restatement

Positive Trial Results

Financial Results

Financial Results

Corporate Presentation and ...

Annual Meeting Results

Appointment and Resignation...

Financial Results Announcement

Reverse Stock Split

Financial Results Announcement

Corporate Presentation Upda...

Settlement Agreement for St...

Securities Purchase Agreement

Delisting Notice

Appointment of Dr. Nicholson

Financial Results Announcement

Appointment of Director

Earnings Reports

Appointment of CFO

Compliance regained with Na...

Annual Meeting of Stockholders

Management Change

Sales Agreement with Cowen ...

Earnings Reports

External Links:

Adverum Biotechnologies announced on March 28, 2025, that it will restate its financial statements for 2022 and 2023 due to errors in accounting for tenant improvement allowances related to a lease in North Carolina, affecting non-cash assets and lia

AI Assistant

ADVERUM BIOTECHNOLOGIES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.